Drug intelligence / Profile preview

HER-2 597-626 peptide

Development stage: Preclinical
Lead developer: Indiana University
Modality: Peptides

Overview

HER-2 597-626 is a synthetic peptide derived from the extracellular domain of the human epidermal growth factor receptor 2 (HER2/neu, also known as ERBB2). This peptide corresponds to amino acids 597 through 626 of the HER2 protein. It has been studied as an immunogenic epitope for cancer vaccine development, particularly in breast cancer and other tumors overexpressing HER2. The mechanism involves stimulating an immune response—specifically T-cell responses—against cells expressing the HER2 antigen, potentially leading to anti-tumor effects. The sequence was designed based on regions recognized by therapeutic antibodies such as trastuzumab and pertuzumab[7][9].

Other names: HER2 peptide 597-626HER-2 peptide 597-626HER 2 peptide 597-626HER2(597–626)

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on HER-2 597-626 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HER-2 597-626 peptide.

Explore the full profile